![]() |
Name |
3,7-Dimethyldecane
|
Molecular Formula | C12H26 | |
IUPAC Name* |
3,7-dimethyldecane
|
|
SMILES |
CCCC(C)CCCC(C)CC
|
|
InChI |
InChI=1S/C12H26/c1-5-8-12(4)10-7-9-11(3)6-2/h11-12H,5-10H2,1-4H3
|
|
InChIKey |
VDAVEASVPZDNQB-UHFFFAOYSA-N
|
|
Synonyms |
3,7-DIMETHYLDECANE; Decane, 3,7-dimethyl-; 17312-54-8; 3,7-dimethyl-Decane; 3,7-Dimethyldecane #; DTXSID80864768; CHEBI:183292; LMFA11000382
|
|
CAS | 17312-54-8 | |
PubChem CID | 28468 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 170.33 | ALogp: | 6.1 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 12 | QED Weighted: | 0.499 |
Caco-2 Permeability: | -4.351 | MDCK Permeability: | 0.00001190 |
Pgp-inhibitor: | 0.017 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.56 |
30% Bioavailability (F30%): | 0.916 |
Blood-Brain-Barrier Penetration (BBB): | 0.589 | Plasma Protein Binding (PPB): | 97.34% |
Volume Distribution (VD): | 2.804 | Fu: | 2.28% |
CYP1A2-inhibitor: | 0.923 | CYP1A2-substrate: | 0.443 |
CYP2C19-inhibitor: | 0.507 | CYP2C19-substrate: | 0.809 |
CYP2C9-inhibitor: | 0.593 | CYP2C9-substrate: | 0.817 |
CYP2D6-inhibitor: | 0.138 | CYP2D6-substrate: | 0.075 |
CYP3A4-inhibitor: | 0.1 | CYP3A4-substrate: | 0.15 |
Clearance (CL): | 7.733 | Half-life (T1/2): | 0.127 |
hERG Blockers: | 0.033 | Human Hepatotoxicity (H-HT): | 0.018 |
Drug-inuced Liver Injury (DILI): | 0.074 | AMES Toxicity: | 0.005 |
Rat Oral Acute Toxicity: | 0.031 | Maximum Recommended Daily Dose: | 0.029 |
Skin Sensitization: | 0.817 | Carcinogencity: | 0.052 |
Eye Corrosion: | 0.992 | Eye Irritation: | 0.976 |
Respiratory Toxicity: | 0.381 |